Related by context. All words. (Click for frequent words.) 70 Phase III AFFIRM 69 phase Ib 69 Phase IIIb clinical 69 dose escalation clinical 69 acyclovir Lauriad R 69 Prostate AdenoCarcinoma Treatment 69 AVADO 69 Pivotal Phase III 69 SPIRIT FIRST 69 Xelox 68 BRIM3 68 GetGoal Phase III 68 Phase Ib clinical 68 CAMMS# 68 oral FTY# 68 BARACLUDE R 68 oral rivaroxaban 68 Phase 1a clinical 68 CUSTOM III 68 SPRYCEL ® 67 BRIM2 67 ORENCIA ® 67 oral ridaforolimus 67 GAMMAGARD 67 TAXUS ATLAS 67 ExTRACT TIMI 67 RECORD1 67 AVERROES 67 RE LY ® 67 ENDEAVOR III 67 HORIZONS AMI 67 Pirfenidone 67 Phase Ib II 67 severe hypercholesterolemia 67 RE SURGE 67 CIMZIA ™ 66 ACTEMRA TM 66 placebo controlled Phase III 66 MAGE A3 ASCI 66 placebo controlled Phase 66 ADVANCE PD 66 riociguat 66 confirmatory clinical 66 CALGB # [002] 66 BR.# 66 UPLYSO 66 HuMax EGFr 66 Phase Ib IIa 66 Phase Ib study 66 phase IIa 66 galiximab 66 forodesine 66 preclinical efficacy 66 ZOLINZA 66 randomized Phase IIb 66 RoACTEMRA 66 REMINYL ® 66 CIMZIA TM 65 phase IIb clinical 65 relapsed MM 65 placebo controlled clinical 65 RANK Ligand inhibitor 65 ILLUMINATE 65 EVEREST II 65 MERLIN TIMI 65 fidaxomicin Phase 65 Efficacy Results 65 trastuzumab DM1 T DM1 65 CLARITY study 65 ongoing Phase 1b 65 R# #mg BID 65 alvespimycin 65 dosing cohorts 65 Ophena TM 65 rALLy trial 65 Traficet EN 65 Tarceva TM 65 standard chemotherapy regimen 65 TRANSFORMS 65 NVA# 65 Targretin capsules 65 registrational Phase 65 huC# DM4 65 relapsing remitting MS RRMS 65 Cimzia TM 65 ORAL Sync 65 BCIRG 65 Dacogen injection 65 ENDEAVOR II 65 Golimumab 65 HCV RESPOND 2 65 interferon gamma 1b 65 PERSEUS 65 Pivotal Phase 65 Long Term Efficacy 65 viral kinetic 65 CTAP# Capsules 65 AVOREN 65 Amrubicin 65 ToGA 65 ENDEAVOR IV 65 Folfox 65 fidaxomicin Phase 3 64 Phase Ib 64 PRE SURGE 64 Pivotal Trial 64 Combination REOLYSIN R 64 Teriflunomide 64 CIMZIA TM certolizumab pegol 64 Phase 1b clinical 64 Azedra 64 Meets Primary Endpoint 64 EOquin TM 64 randomized controlled multicenter 64 EDEMA3 64 Hsp# Inhibitor 64 phase IIb study 64 refractory chronic lymphocytic 64 treatment naive genotype 64 Severe Sepsis 64 ARCOXIA 64 Phase IIb III 64 HCV SPRINT 64 Catena ® 64 assessing T DM1 64 FOLOTYN ® 64 STRIDE PD 64 multicenter Phase 64 RAPTIVA 64 iclaprim 64 ruxolitinib 64 Achieves Primary Endpoint 64 axitinib 64 dose cohort 64 XL# SAR# 64 ® bortezomib 64 APPRAISE 64 MIVI III 64 multicenter placebo controlled 64 Initiates Enrollment 64 randomized Phase III 64 Raptiva ® 64 TYKERB 64 Randomized Phase 64 phase IIIb 64 NP2 Enkephalin 64 OncoVEX GM CSF 64 Afatinib 64 bazedoxifene conjugated estrogens 64 Tasigna nilotinib 64 lumiliximab 64 LymphoStat B TM 64 Aflibercept 64 blinded randomized placebo controlled 64 neratinib 64 phase IIa clinical 64 Brentuximab Vedotin SGN 64 plus dexamethasone 64 ACUITY trial 64 Cimzia ® certolizumab pegol 64 phase 2a 64 COMFORT II 63 ORENCIA R 63 sNDA submission 63 SPIRIT IV 63 Safinamide 63 enzastaurin 63 LUMINATE 63 Pharmacokinetic 63 LUX Lung 63 Glufosfamide 63 Completes Patient Enrollment 63 multicenter Phase II 63 rhLF 63 Prospective Randomized 63 Natalizumab 63 SUCCEED trial 63 Tracleer R 63 SUTENT ® 63 Randomized Double blind 63 virus HCV protease inhibitor 63 EGS# 63 brivaracetam 63 NOXAFIL Oral Suspension 63 Pivotal Clinical Trial 63 crizotinib PF # 63 SNT MC# 63 Sibutramine Cardiovascular Outcomes 63 elotuzumab 63 Initiated Phase 63 ponatinib 63 Keppra XR 63 rALLy clinical trial 63 Edge STudy 63 ELACYT 63 Romiplostim 63 CRMD# 63 paliperidone ER 63 phase IIb trial 63 Initiate Phase 63 PROMACTA 63 prospective multicentre 63 relapsed myeloma 63 Endeavor drug eluting 63 MERIT ES 63 oxymorphone ER 63 Shows Efficacy 63 alfa 2a 63 ONCONASE R 63 Dasatinib 63 HGS ETR2 63 XGEVA 63 evaluating tivozanib 63 Femara letrozole 63 ENESTnd 63 Tumor Response 63 NSABP B 63 SEROQUEL R 63 Cloretazine 63 TYSABRI natalizumab 63 subcutaneous PRO 63 mertansine 63 Randomized Phase II 63 Phase IIB clinical 63 XIENCE V PROMUS Stent 63 SNT-MC#/idebenone 63 Phase IIIB IV 63 Ophena 63 Pegloticase 63 sorafenib tablets 63 baminercept 63 Sorafenib HCC Assessment 63 Matrix Phase 2b 63 Phase III Clinical Trial 63 LymphoStat B belimumab 63 Xeloda ® 63 YONDELIS 63 Corlux 63 PRECiSE 63 BOLDER II 63 trastuzumab emtansine T DM1 63 efficacy tolerability 63 CLORETAZINE TM VNP#M 63 LAF# 63 ACTEMRA 63 lomitapide 63 Investigational Compound 63 azilsartan medoxomil 63 Civacir 62 indiplon capsules 62 AZILECT R 62 Octreolin 62 ZACTIMA 62 number NCT# ClinicalTrials.gov 62 PreCISe 62 Vicriviroc 62 PDX pralatrexate 62 Active Ulcerative Colitis 62 Ambrisentan 62 Phase IIIb 62 arzoxifene 62 LibiGel ® 62 Bezielle 62 Phase III VISTA 62 Presents Positive Preclinical 62 multicenter multinational 62 SVR# 62 SYNERGY Stent 62 SYMMETRY trial 62 LEVADEX ™ 62 pain palliation 62 Phase 2a clinical 62 Phase III Trial 62 Phase 2b study 62 Oral Fingolimod 62 Jevtana 62 aflibercept 62 alvimopan 62 AIR CF2 62 Orazol 62 eltrombopag 62 induced macular edema 62 MADIT II 62 relapsed MCL 62 Initiates Phase II 62 Eloxatin ® 62 EXPAREL ™ 62 BAY #-# 62 EchoCRT 62 CLARITY TIMI 62 Taxotere ® 62 canakinumab 62 PROVENGE ® 62 ICON7 62 Desvenlafaxine Succinate 62 INSPIRE Trial Phase III 62 CCX# B 62 pharmacokinetics PK 62 ASSERT trial 62 cediranib 62 relapsed refractory multiple myeloma 62 evaluating mipomersen 62 Omacetaxine 62 elacytarabine 62 KRAS status 62 Board DSMB 62 Intervention Effectiveness 62 deforolimus 62 tipranavir 62 THALOMID 62 Ocrelizumab 62 CoFactor 62 Phase 1b trial 62 hoFH 62 Augment Injectable 62 Ixempra 62 Randomized Double Blind 62 Demonstrates Significant 62 Hormone Refractory Prostate Cancer 62 Tekamlo 62 ganetespib 62 Zenvia Phase III 62 romidepsin 62 Patient Outcomes 62 teriflunomide 62 VELCADE melphalan 62 demonstrated clinically meaningful 62 ritonavir boosted 62 oral methylnaltrexone 62 glufosfamide 62 tocilizumab 62 APEX AMI trial 62 Platelet Inhibition 62 Elagolix 62 HORIZONS AMI trial 62 Altastaph 62 pharmacokinetic PK study 62 Quinamed 62 Pharmacokinetics PK 62 Phase 1b 62 Rhucin R 62 NO# [002] 62 Phase 2a trial 62 Cloretazine ® 62 APEX PD 62 Phenoptin 62 Pemetrexed 62 velafermin 62 fosbretabulin 62 phase IIb 62 ATACAND 62 unique alkylating agent 62 successfully commercialize Iluvien 62 acyclovir Lauriad ® 62 oral deforolimus 62 NSABP C 62 Ceflatonin ® 62 FASLODEX 62 Zemplar Capsules 62 KRN# 62 Relapsed Multiple Myeloma 62 sunitinib Sutent 62 Oncotype DX colon cancer 62 Ozarelix 62 Xanafide 62 Aplidin 62 SABCS 62 statistically significant efficacy 62 Phase III HEAT 62 NEVO ™ 62 Empatic ™ 62 CINQUIL 62 AIR CF1 62 GVAX 62 vidofludimus 62 Gemzar ® 62 Clinical Trial Results 62 Phase #/#a 62 active comparator 62 Marketing Authorisation Application 62 Intravitreal 62 ROTATEQ 62 YERVOY 61 ancrod 61 ADAGIO study 61 Tanespimycin 61 multicenter Phase III 61 evaluating Xcytrin 61 Aptivus ® 61 TORISEL 61 desvenlafaxine succinate 61 Dabigatran etexilate 61 randomized controlled Phase 61 DexaSite 61 Phase III placebo controlled 61 BrachySil TM 61 Pivotal Study 61 ARCALYST ® 61 Phase IIa trial 61 MGN# 61 LCP AtorFen 61 maximally tolerated dose 61 Androxal TM 61 TELCYTA 61 placebo controlled multicenter 61 ongoing Phase IIIb 61 INCB# [001] 61 multicenter randomized placebo controlled 61 HoFH 61 metastatic HRPC 61 Phase #b/#a 61 dose escalation phase 61 ROCKET AF 61 Dalbavancin 61 everolimus eluting stents 61 JAK inhibitor 61 mg administered orally 61 MAA submission 61 SinuNase TM 61 vivo toxicology 61 Carotid Revascularization Endarterectomy vs. 61 icatibant 61 Genz # 61 acetonide FA 61 randomized multicenter trial 61 Pharmacodynamic 61 Tekturna HCT 61 midstage clinical 61 Certican 61 PROTECT AF 61 TYGACIL 61 Phase 2b kidney transplant 61 lenalidomide Revlimid R 61 TO AVOID PREGNANCY WHILE 61 R#/MEM # 61 Phase IIB 61 landmark ATHENA 61 heFH 61 OncoVEX 61 ularitide 61 sorafenib Nexavar 61 CRLX# 61 NEUVENGE 61 Prestara 61 APTIVUS r 61 CONBRIZA 61 pegylated interferon alpha 61 AVASTIN 61 EDARBI 61 JAK Inhibitor 61 Presents Positive 61 RRMS patients 61 ARIKACE 61 Hedgehog Pathway Inhibitor 61 Oral Calcitonin 61 plus prednisone 61 Pixuvri 61 Adjuvant Treatment 61 Phase III Clinical Trials 61 pharmacokinetic PK 61 T Pred 61 PRIMO CABG2 61 Zarnestra 61 Val HeFT 61 pioglitazone HCl 61 Cloretazine R VNP#M 61 CLL8 61 Levoleucovorin 61 IMPACT DCM 61 nasal calcitonin product 61 SPIRIVA HandiHaler 61 Curaxin CBLC# 61 Alvesco R 61 briakinumab 61 adalimumab Humira 61 Cethromycin 61 statistically significant superiority 61 REG1 Anticoagulation System 61 adjuvant colon cancer 61 EXPAREL TM 61 EmbraceAC 61 pemetrexed Alimta 61 ON #.Na 61 Boceprevir 61 dose escalation trial 61 TMC# [002] 61 Phase IIA 61 novel VDA molecule 61 CYPHER ® Sirolimus eluting 61 Deforolimus 61 ARIXTRA 61 NEBIDO 61 melphalan prednisone 61 Archexin 61 Rasilez Tekturna 61 EDEMA4 61 multicenter randomized controlled 61 PRIMO CABG 61 Antitumor Activity 61 DSMB recommended 61 VIVITROL ® 61 PCI ExTRACT TIMI 61 Pooled Analysis 61 Mylotarg 61 placebo controlled studies 61 Xcytrin R 61 Vascugel ® 61 IMPACT IMmunotherapy 61 docetaxel chemotherapy 61 Committee IDMC 61 huN# DM1 61 MabCampath 61 LIALDA 61 TAXUS VI 61 RSR# 61 HGS# 61 morphometric vertebral fractures 61 Marketing Authorization Application 61 compound INCB# 61 Onrigin 61 Phase III psoriasis 61 Entereg R 61 Sprycel dasatinib 61 SPIRIT III 61 miconazole Lauriad ® 61 OncoVex 61 rindopepimut 61 docetaxel Taxotere ® 61 delafloxacin 61 EDEMA3 trial 61 trastuzumab DM1 61 Capsules CII 61 Ereska 61 TELINTRA 61 Phase #/#a trial 61 Free Survival PFS 61 octreotide acetate 61 Temsirolimus 61 CARE HF 61 Restanza TM 61 metastatic CRC 61 ocular formulation 61 CORDAPTIVE 61 RE LY 61 BARI 2D 61 Anturol TM 61 Triapine 61 DCVax R Brain 61 Endeavor Drug Eluting 61 relapsed multiple myeloma 61 PROVENGE sipuleucel T 61 oral prodrug 61 Phase III ADT 61 Q#IR 61 naïve HCV 61 TREANDA 61 dosing cohort 61 Carfilzomib 61 recurrent metastatic ovarian cancer 61 R adalimumab 61 prospective multicenter randomized 61 torezolid phosphate 60 supplemental biologics 60 amrubicin 60 Cloretazine R 60 sunitinib malate 60 EndoTAG TM -1 60 Heplisav 60 PARTNER Trial 60 ASA# 60 Tolerability 60 humanized interleukin 6 60 gadobutrol 60 DEB# 60 Hodgkin lymphoma HL 60 HuMax CD4 60 randomized blinded 60 ALGRX 60 bicifadine 60 tipifarnib 60 dose escalation Phase 60 certolizumab 60 multicenter prospective 60 RNAi Therapeutic 60 Romidepsin 60 SCH # 60 ACAPODENE 60 Acute Ischemic Stroke 60 LCP Tacro 60 Phase 2b Clinical Trial 60 Microplasmin 60 PRISTIQ 60 Metastatic Colorectal Cancer 60 LibiGel Phase III 60 randomized Phase 2b 60 Proellex TM 60 Vidaza azacitidine 60 placebo controlled clinical trials 60 SAR# [004] 60 reslizumab 60 cetuximab Erbitux 60 Degarelix 60 multicentre randomized 60 Engerix B 60 nonclinical studies 60 acute PAO 60 #th Annual Interscience 60 Crofelemer budesonide foam 60 Aurexis 60 Tolvaptan 60 viral kinetics 60 colesevelam HCl 60 Pharmacokinetic parameters 60 dirucotide MBP# 60 Phase 2b clinical 60 Raptiva r 60 Clinical Antipsychotic Trials 60 PROactive study 60 lorvotuzumab mertansine 60 myelodysplastic myeloproliferative diseases 60 sipuleucel T 60 omacetaxine 60 nilotinib 60 TAXUS IV 60 clevidipine 60 Phase IIb trials 60 Keppra ® XR 60 angiographic outcomes 60 BRILINTA 60 metaglidasen 60 oral chemotherapeutic agent 60 TroVax ® 60 PKC# 60 Phase #b/#a clinical 60 TAXUS Liberte Long 60 Advagraf 60 BARACLUDE ® 60 granted Ortec 60 Thorough QT 60 REVLIMID lenalidomide 60 balsalazide tablet 60 RLAI 60 Virologic 60 non nucleoside inhibitor 60 Initiate Clinical Trial 60 hemostatic efficacy 60 Phase IIb Trial 60 tolerability profiles 60 Panzem R 60 APTIVUS 60 XL# XL# XL# 60 rilpivirine 60 PROSTVAC TM 60 cancer neuroendocrine tumor 60 INTEGRILIN R eptifibatide Injection 60 abiraterone acetate 60 Phase IIa 60 Immunogenicity 60 TORISEL TM 60 Cleviprex TM clevidipine 60 Sandostatin LAR Depot 60 MEK Inhibitor 60 motesanib 60 evaluating REVLIMID 60 LymphoStat B 60 IL# PE#QQR 60 BLA filing 60 Mipomersen 60 azacitidine 60 JOULFERON 60 thalidomide Thalomid 60 Rasilamlo 60 NDA Submission 60 panitumumab Vectibix 60 pegaptanib 60 pivotal bioequivalence 60 PSMA ADC 60 Newly Diagnosed Multiple Myeloma 60 QTc prolongation 60 NGX# 60 Clinical Trial Evaluating 60 EXPLORE Xa 60 tenofovir emtricitabine 60 CHAMPION PCI 60 ospemifene 60 Marketing Authorization Applications 60 Aryplase 60 ABSORB clinical 60 Diabetic Macular Edema 60 Plicera 60 MGd 60 AZILECT ® 60 FAME Study 60 Campath alemtuzumab 60 Cimzia ® 60 Linagliptin 60 Patient Enrollment 60 tafamidis 60 ThermoDox ® clinical 60 cladribine tablets 60 Phase IIa clinical 60 mycophenolate mofetil 60 Initiates Phase III 60 abstracts summarizing 60 bazedoxifene 60 KYNAPID 60 Randomized Evaluation 60 Multicenter Automatic Defibrillator Implantation 60 Biologics License Application BLA 60 R sorafenib tablets 60 PD LID 60 CATIE AD 60 evaluating Vectibix 60 FTY# 60 sustained virologic response 60 Cimzia R 60 pertuzumab 60 PIX# [002] 60 BRAF inhibitor 60 albinterferon alfa 2b 60 hemagglutination inhibition HAI 60 Viramidine 60 entinostat 60 QNEXA 60 Phase 2b monotherapy 60 VESTASYNC 60 TASKi3 60 RAD# everolimus 60 Torisel 60 ABSORB trial 60 Biological License Application 60 CAPACITY trials 60 Oracea TM 60 analgesic efficacy 60 selective modulator 60 registrational trial 60 PROCHYMAL 60 AIR2 Trial 60 intravenous dosing 60 rALLy 60 registrational 60 ATPace TM 60 subcutaneous formulation 60 systemic anaplastic large 60 Raptiva R 60 INC# 60 antiviral efficacy 60 PEG interferon 60 subcutaneous methylnaltrexone 60 solithromycin 60 Multicenter 60 plus prednisone prednisolone 60 IMA# 60 dirucotide 60 Avastin bevacizumab 60 CAELYX 60 investigational protease inhibitor 60 Panzem R NCD 60 paclitaxel eluting stents 60 dose cohorts 60 trodusquemine 60 Forodesine HCl 60 CIP TRAMADOL ER 60 Dyloject TM 60 regorafenib 60 Telik logo TELINTRA 60 faropenem 60 intravascular hemolysis 60 Fondaparinux 60 prucalopride 60 ACZ# 60 Initiate Phase II 60 MIRCERA 60 comparator arm 60 Peginterferon alfa 2b 60 aclidinium 60 Study Evaluating 60 Phase III confirmatory 60 secondary efficacy endpoints 60 BLOOM DM 60 catheter occlusion 60 intravitreal insert 60 tipranavir r 60 PF # [002] 60 Betaferon ® 60 mapatumumab 60 talactoferrin 60 GATTEX TM 60 Successfully Completes Phase 60 CUSTOM II 60 R Bortezomib 60 FOLFOX6 60 albiglutide 60 phase Ib clinical 60 TWYNSTA ® 60 Granted Orphan Drug 60 Tavocept 60 Initiate Phase III 60 recurrent metastatic 60 Perifosine KRX 60 OvaRex ® MAb 60 randomized multicenter Phase III 60 Enzastaurin 60 novel oral anticoagulant 60 Nymox NX 60 Vicinium TM 60 RE MODEL 60 Rebif ® 60 adecatumumab MT# 60 plus COPEGUS 60 nab paclitaxel 60 Vitaxin 60 GSK# [001] 60 INCB# [003] 60 By JENNIFER LEARN 60 paclitaxel poliglumex 60 treatment naïve genotype 60 BrachySil 60 INTEGRILIN R 60 darunavir r 60 CURRENT OASIS 7 60 fluvastatin 60 Patients Receiving 60 Onconase 60 Sapacitabine 60 demonstrated antitumor activity 60 Telatinib 60 IRX 2 60 VFEND 60 ISTODAX ® 60 CD# CEA 60 ACCORD Lipid 60 Prolongs Survival 60 bosutinib 60 phase IIb III 60 desvenlafaxine 60 OMAPRO ™ 60 Endovascular Valve Edge 60 prospective multicenter 60 Accelerated Approval 60 Epratuzumab 59 LEVAQUIN ® 59 Arikace 59 JANUVIA 59 rasagiline tablets 59 mg/m2 cohort 59 oral salmon calcitonin 59 GOUT 59 Phase 1b clinical trials 59 GRN# 59 opioid induced bowel dysfunction 59 heterozygous FH 59 liposome injection 59 Dupuytren Contracture 59 liver resection surgeries 59 Hepatocellular Carcinoma HCC 59 Genasense ® oblimersen 59 low dose cytarabine 59 Long Lesion 59 senicapoc 59 Personalized Immunotherapy 59 recurrent glioblastoma multiforme 59 omacetaxine mepesuccinate 59 ELND# 59 Genasense ® 59 adjuvant GIST 59 Cipralex ® 59 eprotirome 59 rilonacept 59 IRESSA 59 Pegasys ® 59 Rivaroxaban 59 Phase IIb clinical trials 59 prospective randomized placebo 59 Hepatotoxicity 59 brand ciclesonide HFA 59 EURIDIS 59 refractory gout 59 NEVO RES 59 ATL/TV# 59 Dose Escalation 59 Angiox ® 59 ixabepilone 59 Nexavar sorafenib 59 Alocrest 59 phase III ACCLAIM 59 neurologic progression 59 Neupro R 59 Valsartan 59 ZOMIG R 59 ARB telmisartan 59 Revlimid lenalidomide 59 Locteron ® 59 ProSavin 59 docetaxel Taxotere R 59 Hepsera adefovir dipivoxil 59 BETAS 59 tramiprosate Alzhemed TM 59 AGILECT R 59 Tezampanel 59 HIF PHI 59 PREVENT IV 59 randomized discontinuation trial 59 TASKi2 59 BLA submission 59 Rhucin ® 59 LEUKINE 59 ANCHOR trial 59 vemurafenib 59 Ragweed Allergy 59 TMC# C# 59 Vidaza R 59 radezolid 59 PRN FDA Approves 59 Completes Patient Enrolment 59 CANCIDAS 59 NATRECOR ® 59 Ventavis 59 Warfarin Coumadin 59 metastatic hormone refractory 59 Sipuleucel T 59 Pertuzumab 59 rNAPc2 59 SUSTENNA TM 59 Velcade bortezomib 59 Postmarketing 59 RSD# oral 59 tesmilifene 59 Firazyr 59 tolerability pharmacokinetics 59 lumiracoxib 59 Abatacept 59 Clolar ® 59 Phase 2a 59 SPARLON 59 Seliciclib 59 Phase Ia 59 ® darbepoetin alfa 59 REMICADE ® 59 Sym# 59 elagolix 59 Demonstrates Sustained 59 Bucindolol 59 Diovan HCT 59 PHX# 59 Zoraxel 59 ThermoDox R 59 Allovectin 7 59 adult chronic ITP 59 KAPIDEX 59 Pegasys plus Copegus 59 Stent Restenosis 59 Pruvel 59 Fludara ® 59 Pulmonary Arterial Hypertension 59 RIO Lipids 59 Ceflatonin 59 Canvaxin 59 ENESTnd Evaluating Nilotinib Efficacy 59 hour bronchodilation 59 R lenalidomide 59 lucinactant 59 Adalimumab 59 randomized controlled clinical trials 59 V Everolimus Eluting Coronary 59 oral picoplatin 59 ® pioglitazone HCl 59 MYCAMINE 59 Tocilizumab 59 aripiprazole Abilify 59 ® decitabine 59 Glybera R 59 PEARL SC 59 Virulizin ® 59 tanespimycin 59 PEGINTRON TM 59 Bayer HealthCare Onyx Pharmaceuticals 59 NLX P# 59 Perifosine 59 Zenvia ™ 59 EMPHASIS HF trial 59 worsening thrombocytopenia 59 nucleotide analogue 59 PERSEUS clinical program 59 sitaxsentan 59 Premarket Approval Application 59 vinorelbine tartrate 59 PXD# 59 Presents Preclinical 59 Phase 2b Study 59 fully bioabsorbable 59 eprodisate Fibrillex TM 59 ORAL Solo 59 ofatumumab 59 Simulect 59 COPAXONE R 59 DDP# 59 Phase III multicenter 59 SPRYCEL